about
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer.Minor-but-Complex Liver Resection: An Alternative to Major Resections for Colorectal Liver Metastases Involving the Hepato-Caval ConfluenceDissecting signaling pathways in hepatocellular carcinoma: new perspectives in medical therapy.Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review.Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.Second-line therapy for advanced pancreatic cancer: evaluation of prognostic factors and review of current literature.Multimodality treatment of locally advanced squamous cell carcinoma of the oesophagus: A comprehensive review and network meta-analysis.Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors.Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer.Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validationComment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.Body mass index and impaired fasting blood glucose as predictive factor of time to progression (TTP) in cetuximab-based colorectal cancer treatment.FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO).Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?Bone metastases in biliary cancers: A multicenter retrospective surveyMulticenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study ProtocolSecond-line chemotherapy in advanced biliary cancer: the present now will later be pastPD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLCStereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal CancerPrognostic value of CD133 caused by mutant K-Ras and B-Raf--letterNot only chemotherapy in the second-line treatment of metastatic gastric cancerSingle-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-OncologyLong-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factorsMoving beyond sorafenib alone in advanced hepatocellular carcinoma: is hepatic arterial infusion chemotherapy the best option?Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directionsImmune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancerTotal neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trialValidated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancerEarly Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort StudyPrediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validationsFOLFIRINOX Adjuvant Therapy for Pancreatic Cancer
P50
Q31033443-9025B019-BE5F-4253-B942-E9A59799B251Q33555296-0D54D4FE-EDB0-43DD-B314-3AE9D7DC4FEEQ35836756-47DE5E65-FB8A-44AE-9A69-977FB1EDB20BQ36153577-032B1F98-749E-475B-8CD7-B6F7756D475BQ38184582-3CD777F4-1BD2-4FB1-A95A-CDF69BBBF249Q38216007-9FAF6C20-2DD5-467B-BE0B-D862BC79C4DEQ38599120-7C2316EC-BDDE-4101-B3C7-DFFCE3E0312DQ38736208-1D1BF404-6C3B-48F8-879B-EDF2C2FC870FQ39287823-72E5F713-4699-4B6A-8920-6BE9A68A325CQ39320938-D9E0F3CD-7FFB-450A-9D51-2DA3DBD0AF41Q39869626-E9862C4D-99C6-4E4B-A53B-C9414534E699Q40380730-89FF0A0E-98C5-47FE-8507-244B2CF50FEDQ40495250-B82FE19C-10C6-4262-9772-2F7F7F5CF6E7Q41533087-012B60FB-E2E5-4A81-A8E7-E8BA40B892D1Q42005022-5B01C3EF-D154-4A4B-AD26-810DADBAFCF8Q42927054-FDBB26CD-3C37-46BC-BDB0-1F6767227F55Q43649036-57C74DEB-B6ED-49C2-899B-4FBEEEBC2AEFQ47915753-05ED8F4C-0E67-4902-AD42-09CA8280FA08Q49571137-DC349148-FBAA-4BBE-8E91-6C7379DCCDE1Q49959389-47B49337-A8CB-4D1A-B8FA-A7151BA6414CQ51541898-5BB82DFC-6F87-4BDA-A6E5-34B2DFF3A155Q53067016-A3F2CF25-9FF2-4257-8BA4-F6F0D9BE8926Q56387056-8A12FE50-A395-46CF-84C4-436E40A4C369Q56927812-DD0153BB-52D1-4231-A7DE-179B046A62A3Q56971957-E602CE45-1175-46DC-A99B-F0FB527F7F01Q61288605-0E26F339-D0D8-486F-B181-471AC2E027C6Q62652389-F08DB3EA-E3D7-4367-8824-828F024E7CDEQ84587772-AE455CF7-9015-4653-86FF-13E8D5FA2BE4Q87195636-8CF795E0-CB04-4FF3-8C1F-F61D721BA2CAQ88755859-FC42F86F-C3E5-41C7-8922-975FDB71D4DEQ88959859-45F2E3B6-2151-45B9-9CEF-D5D25165B9BEQ89016065-C3A01D5E-458A-4AF0-BE67-DC5B6930B989Q89344790-C7CD84C5-9A14-4469-A0B4-66DB24225CF4Q89977152-FF4E23AE-0DC7-4B91-B686-3A31A507AE61Q90298780-64361457-1744-48BD-AC21-2808D333A67DQ91440835-6E89AD6F-2838-4AD2-A8AE-07A24D8F9FACQ91468491-D0279FBC-464B-4CDF-BC4D-22A0C41BECCBQ91658345-F340C5B7-6C79-47CF-99B5-4D5763955FFFQ92076296-B41FC98D-1F7B-47FF-AFAE-92C22C7116CBQ92505344-8D27A084-1E79-43C7-825A-D65F83B25449
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Caterina Vivaldi
@ast
Caterina Vivaldi
@en
Caterina Vivaldi
@es
Caterina Vivaldi
@nl
type
label
Caterina Vivaldi
@ast
Caterina Vivaldi
@en
Caterina Vivaldi
@es
Caterina Vivaldi
@nl
prefLabel
Caterina Vivaldi
@ast
Caterina Vivaldi
@en
Caterina Vivaldi
@es
Caterina Vivaldi
@nl
P106
P1153
55338330900
P21
P31
P496
0000-0001-9307-2326